The publisher, the industry analysis specialist, has released its latest report, “Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Indonesia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by the publisher's team of industry experts.
Indonesia is one of the fastest-growing countries in the Association of Southeast Asian Nations (ASEAN) region, making it one of the most alluring emerging markets for pharmaceutical companies seeking to expand in the Asia-Pacific region. Indonesia's pharmaceutical market was worth $3.6 billion in 2012, which increased at a Compound Annual Growth Rate (CAGR) of 10.2% to $5.3 billion in 2016 in terms of US dollars. The market value is expected to grow further and is forecast to reach $15.4 billion by 2027. Indonesia's medical devices market was valued at $2.9 billion in 2019, which increased to $3.6 billion in 2021 at a CAGR of 11.6%. The market value is expected to grow further and is forecast to reach $6.2 billion by 2026. In February 2022, the Indonesian Ministry of Health (Kemenkes, MOH) announced an update in the e-procurement system (e-Katalog) as per which the Government Agency for Procurement of Goods (Lembaga Kebijakan Pengadaan Barang/ Jasa Pemerintah, LKPP) along with the MOH and Corruption Eradication Commission (Komisi Pemberantasan Korupsi, KPK) will be responsible for reviewing the medical devices before adding them in the e-Katalog. The rising demand for pharmaceuticals and medical devices during COVID-19 has made the pharmaceutical and medical device sectors crucial to the development of Industry 4.0. Therefore, the Indonesian government emphasizes on the digital transformation of the pharmaceutical and medical device industries.
Indonesia is one of the fastest-growing countries in the Association of Southeast Asian Nations (ASEAN) region, making it one of the most alluring emerging markets for pharmaceutical companies seeking to expand in the Asia-Pacific region. Indonesia's pharmaceutical market was worth $3.6 billion in 2012, which increased at a Compound Annual Growth Rate (CAGR) of 10.2% to $5.3 billion in 2016 in terms of US dollars. The market value is expected to grow further and is forecast to reach $15.4 billion by 2027. Indonesia's medical devices market was valued at $2.9 billion in 2019, which increased to $3.6 billion in 2021 at a CAGR of 11.6%. The market value is expected to grow further and is forecast to reach $6.2 billion by 2026. In February 2022, the Indonesian Ministry of Health (Kemenkes, MOH) announced an update in the e-procurement system (e-Katalog) as per which the Government Agency for Procurement of Goods (Lembaga Kebijakan Pengadaan Barang/ Jasa Pemerintah, LKPP) along with the MOH and Corruption Eradication Commission (Komisi Pemberantasan Korupsi, KPK) will be responsible for reviewing the medical devices before adding them in the e-Katalog. The rising demand for pharmaceuticals and medical devices during COVID-19 has made the pharmaceutical and medical device sectors crucial to the development of Industry 4.0. Therefore, the Indonesian government emphasizes on the digital transformation of the pharmaceutical and medical device industries.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Indonesia, and includes:
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, Novartis, GlaxoSmithKline (GSK), Merck, and Kalbe.
- Profiles and SWOT analyses of the major players in the medical device market: Abbott, Fresenius, GE Healthcare, Terumo, and Smith and Nephew.
- An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in healthcare market, HealthTech landscape, reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices.
- Detailed analysis of the country's healthcare policy highlights, demographics, healthcare infrastructure and healthcare expenditure.
- An overview of the opportunities for and challenges to growth in the Indonesian healthcare market.
Reasons to Buy
This report will enhance your decision-making capability by allowing you to:
- Develop business strategies by understanding the trends shaping and driving the Indonesian healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact the Indonesian healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors' performance
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership
Table of Contents
1. Table of Contents
2. Executive Summary
3. Overview of Pharmaceutical Market
4. Overview of Medical Devices Market
5. Pharmaceutical and Medical Devices Market - Drivers and Barriers
6. Deal Analysis
7. Healthtech Landscape
9. Country Healthcare Landscape
13 Appendix
List of Tables
List of Figures
